Eckert & Ziegler Reports Strong Financial Performance in 2025

Berlin-based Eckert & Ziegler SE achieved significant financial growth in 2025, as indicated by preliminary figures. The company's sales reached approximately €312 million, marking a 5% increase from the previous year. Furthermore, the EBIT before special items rose to around €78 million, up 18% from 2024. Net income also saw a substantial rise to €48 million from €33.3 million in the prior year.

Eckert & Ziegler, a key player in the isotope-related components field for nuclear medicine and radiation therapy, continues to expand its services for the radiopharmaceutical industry. The full audited financial report for 2025, along with future forecasts, is set to be published on 26 March 2026. The company's performance keeps it well-positioned within the TecDAX index.